Plurihormonal pituitary adenomas: immunostaining of all pituitary hormones is mandatory for correct classification
- PMID: 11532042
- DOI: 10.1046/j.1365-2559.2001.01204.x
Plurihormonal pituitary adenomas: immunostaining of all pituitary hormones is mandatory for correct classification
Abstract
Aims: We studied the clinicopathological characteristics of plurihormonal pituitary adenomas.
Methods and results: The study material included 167 plurihormonal adenomas, which consisted of 31% of the surgically removed pituitary adenomas that we collected during a 12-year period. The mean age of patients with plurihormonal adenoma was 45.7 years (range 13-75 years). There were 86 men and 81 women. All tumours were fully classified by immunohistochemical staining for seven pituitary hormones or subunits. Thirty immunohistochemical subtypes of plurihormonal adenomas were recognized. Hormonal symptoms were present in 70% of patients, while serum hormonal levels were increased in 89% of patients. Most patients had symptoms related to only one of the hormones and only 7% of patients had symptoms related to two hormones. The most common hormonal symptom was acromegaly (50%); symptoms related to hyperprolactinaemia ranked second (20%). Double immunostaining of all the possible combinations of the hormones was performed in 30 selected tumours, and they all showed mixtures of hormones in individual adenoma cells in any hormonal combinations studied. The latter finding supported the view that plurihormonal adenomas are monomorphous adenomas.
Conclusions: Plurihormonal adenomas are common pituitary adenomas. Immunohistochemical staining of all pituitary hormones is mandatory for correct classification.
Similar articles
-
Expression of somatostatin receptor subtypes in human pituitary adenomas -- immunohistochemical studies.Endokrynol Pol. 2009 Jul-Aug;60(4):240-51. Endokrynol Pol. 2009. PMID: 19753537
-
Plurihormonality of pituitary adenomas in light of immunohistochemical studies.Endokrynol Pol. 2010 Jan-Feb;61(1):63-6. Endokrynol Pol. 2010. PMID: 20205106
-
Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data.Eur J Endocrinol. 2006 May;154(5):753-8. doi: 10.1530/eje.1.02107. Eur J Endocrinol. 2006. PMID: 16645024
-
Current pathological classification of pituitary adenomas.Acta Neurochir Suppl. 1996;65:1-3. doi: 10.1007/978-3-7091-9450-8_1. Acta Neurochir Suppl. 1996. PMID: 8738481 Review.
-
The 2017 WHO classification of pituitary adenoma: overview and comments.Brain Tumor Pathol. 2018 Apr;35(2):51-56. doi: 10.1007/s10014-018-0314-3. Epub 2018 Apr 23. Brain Tumor Pathol. 2018. PMID: 29687298 Review.
Cited by
-
Pathologic and clinical features of pituitary adenomas showing TSH immunoreactivity.Pituitary. 2013 Sep;16(3):287-93. doi: 10.1007/s11102-012-0419-3. Pituitary. 2013. PMID: 22869255
-
Concurrent somatotroph and plurihormonal pituitary adenomas in a cat.J Feline Med Surg. 2013 Oct;15(10):945-52. doi: 10.1177/1098612X13483461. Epub 2013 Apr 3. J Feline Med Surg. 2013. PMID: 23553410 Free PMC article.
-
Hormone markers in pituitary adenomas: changes within last decade resulting from improved method.Endocr Pathol. 2003 Spring;14(1):49-54. doi: 10.1385/ep:14:1:49. Endocr Pathol. 2003. PMID: 12746562
-
Retrospective Analysis of Cushing's Disease with or without Hyperprolactinemia.Int J Endocrinol. 2014;2014:919704. doi: 10.1155/2014/919704. Epub 2014 Nov 23. Int J Endocrinol. 2014. PMID: 25506361 Free PMC article.
-
Analysis of differential gene expression in plurihormonal pituitary adenomas using bead-based fiber-optic arrays.J Neurooncol. 2012 Jul;108(3):341-8. doi: 10.1007/s11060-011-0792-1. Epub 2012 May 16. J Neurooncol. 2012. PMID: 22588334
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical